华蟾素联合多西他赛单药化疗治疗高龄晚期非小细胞肺癌的临床观察  

Clinical observation of Cinobufotalin combined with Docetaxel on advanced non-small cell lung cancer in the elderly

作　　者：张伟[1] 黄传江[1] 黄海波[1] 彭笑怒[1] 仲崇文[1] 

机构地区：[1]青岛大学医学院附属烟台毓璜顶医院胸外科,山东烟台264000

出　　处：《实用临床医药杂志》2011年第17期95-97,共3页Journal of Clinical Medicine in Practice

基　　金：中国高校医学期刊临床专项资金资助项目(11120011)

摘　　要：目的观察华蟾素注射液联合多西他赛单药化疗治疗高龄晚期非小细胞肺癌的临床疗效。方法高龄晚期非小细胞肺癌患者76例,分为联合治疗组46例及单纯化疗组30例。2组均采用多西他赛单药方案,联合治疗组加用华蟾素注射液联合静脉滴注,完成2周期后,评价疗效及不良反应。结果联合治疗组总有效率(30.4%)与单纯化疗组(33.3%)比较,差异无统计学意义;联合治疗组生活质量提高率(45.7%)明显高于单纯化疗组(23.3%),差异有统计学意义,而2组在稳定率及生活质量下降率方面差异无统计学意义;联合治疗组的Ⅲ/Ⅳ度不良反应发生率均低于单纯化疗组。结论华蟾素注射液联合多西他赛单药化疗治疗高龄晚期非小细胞肺癌能明显改善临床症状,减轻化疗毒副反应,从而提高生活质量,值得临床推广应用。Objective To observe the clinical effect of Cinobufotalin combined with Docetaxel on advanced non-small cell lung cancer in the elderly.Methods Seventy-six cases of advanced non-small cell lung cancer were divided into combined group（n=46） and single group（n=30）.Both groups were given Docetaxel chemotherapy.The combined group was added Cinobufotalin vein injection.The efficiency was evaluated after two courses.Results There was no statistical difference in total effective rate between the combined group（30.4%） and the single group（33.3%）.The increasing rate of life quality in the combined group（45.7%） was significantly higher than the single group（23.3%）.There was no statistical difference in the stability rate and decreasing rate of life quality between the two groups.The incidence rates of adverse reactions at Ⅲ/Ⅳ grade in the combined group were lower than those in single group.Conclusion The therapy of Cinobufotalin combined with Docetaxel on advanced non-small cell lung cancer in the elderly could improve the clinical symptoms,release adverse reactions,and progress the life quality.It is worth to be popularized and applied.

关 键 词：肺癌 非小细胞 高龄 华蟾素 多西他赛 

分 类 号：R734.2[医药卫生—肿瘤]